nach oben

Current Diabetes Reports

Erschienen in:

01.08.2012 | Microvascular Complications—Retinopathy (JK Sun, Section Editor)

Neuroprotection in Diabetic Retinopathy

verfasst von: Cristina Hernández, Rafael Simó

Erschienen in: Current Diabetes Reports | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Diabetic retinopathy (DR) has been considered to be a microcirculatory disease of the retina. However, there is emerging evidence to suggest that retinal neurodegeneration is an early event in the pathogenesis of DR, which may antedate, and also participates in, the microcirculatory abnormalities that occur in DR. Therefore, the study of the underlying mechanisms that lead to neurodegeneration will be essential for identifying new therapeutic targets in the early stages of DR. Elevated levels of glutamate, oxidative stress, the overexpression of the renin-angiotensin system and the upregulation of RAGE play an essential role in the retinal neurodegeneration induced by diabetes. Finally, the balance between the neurotoxic and neuroprotective factors is crucial in determining the survival of retinal neurons. In this review we will focus on neurotrophic factors already synthesized by the retina in physiological conditions as a new therapy strategy for neuroprotection.

Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124–36.PubMedCrossRef

Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin. 2010;26:1587–97.PubMedCrossRef

Lamoureux EL, Wong TY. Diabetic retinopathy in 2011: further insights from new epidemiological studies and clinical trials. Diabetes Care. 2011;34:1066–7.PubMedCrossRef

Javitt JC. Cost savings associated with detection and treatment of diabetic eye disease. PharmacoEconomics. 1995;8 Suppl 1:33–9.PubMedCrossRef

Pelletier EM, Shim B, Ben-Joseph R, Caro JJ. Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis. PharmacoEconomics. 2009;27:479–90.PubMedCrossRef

Heintz E, Wiréhn AB, Peebo BB, et al. Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. Diabetologia. 2010;53:2147–54.PubMedCrossRef

Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. 2007; 298:902–16.

Simó R, Hernández C. Advances in the medical treatment of diabetic retinopathy. Diabetes Care. 2009;32:1556–62.PubMedCrossRef

Simó R, Hernández C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia. 2008;51:1574–80.PubMedCrossRef

10.

Joussen AM, Joeres S. Benefits and limitations in vitreoretinal surgery for proliferative diabetic retinopathy and macular edema. Dev Ophthalmol. 2007;39:69–87.PubMedCrossRef

11.

Barber AJ, Lieth E, Khin SA, et al. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest. 1998;102:783–91.PubMedCrossRef

12.

Lieth E, Gardner TW, Barber AJ, Antonetti DA, Penn State Retina Research Group. Retinal neurodegeneration: early pathology in diabetes. Clin Exp Ophthalmol. 2000;28:3–8.CrossRef

13.

Rungger-Brändle E, Dosso AA, Leuenberger PM. Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2000;4:1971–80.

14.

Lorenzi M, Gerhardinger C. Early cellular and molecular changes induced by diabetes in the retina. Diabetologia. 2001;44:791–804.PubMedCrossRef

15.

Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:283–90.PubMedCrossRef

16.

Asnaghi V, Gerhardinger C, Hoehn T, et al. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes. 2003;52:506–11.PubMedCrossRef

17.

Antonetti DA, Barber AJ, Bronson SK, et al. JDRF Diabetic Retinopathy Center Group. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes. 2006;55:2401–11.PubMedCrossRef

18.

Fletcher EL, Phipps JA, Ward MM, et al. Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr Pharm Des. 2007;13:2699–712.PubMedCrossRef

19.

• Barber AJ, Gardner TW, Abcouwer SF. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011;52:1156–63. In this excellent review the authors give balanced arguments supporting the role of neural and vascular apoptosis in the pathogenesis of DR and define diabetic retinopathy as a form of chronic neurovascular degeneration. PubMedCrossRef

20.

Carrasco E, Hernandez C, Miralles A, et al. Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care. 2007;30:2902–8.PubMedCrossRef

21.

Carrasco E, Hernández C, de Torres I, et al. Lowered cortistatin expression is an early event in the human diabetic retina and is associated with apoptosis and glial activation. Mol Vis. 2008;14:1496–502.PubMed

22.

• Garcia-Ramírez M, Hernández C, Villarroel M et al (2009) Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy. Diabetologia. 2009; 52:2633–41. This paper demonstrates that underproduction of IRBP is an early event in the human diabetic retina and is associated with retinal neurodegeneration. In addition, a dose-dependent downregulation of IRBP mRNA expression and IRBP content was detected with glucose, TNF-alpha and IL-1beta in cultures of Y79 human retinoblastoma cells. Given that IRBP plays a major role in the visual cycle and is essential for the maintenance of photoreceptors, its replacement should be considered a new therapeutic target for DR. PubMedCrossRef

23.

Shirao Y, Kawasaki K. Electrical responses from diabetic retina. Prog Retin Eye Res. 1998;17:59–76.PubMedCrossRef

24.

Ewing FM, Deary IJ, Strachan MW, Frier BM. Seeing beyond retinopathy in diabetes: electrophysiological and psychophysical abnormalities and alterations in vision. Endocr Rev. 1998;19:462–76.PubMedCrossRef

25.

Bearse jr MA, Adams AJ, Han Y, et al. A multifocal electroretinogram model predicting the development of diabetic retinopathy. Prog Retin Eye Res. 2006;25:425–48.PubMedCrossRef

26.

Bronson-Castain KW, Bearse Jr MA, Neuville J, et al. Adolescents with Type 2 diabetes: early indications of focal retinal neuropathy, retinal thinning, and venular dilation. Retina. 2009;29:618–26.PubMedCrossRef

27.

• Harrison WW, Bearse MA, Ng J et al. Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Invest Ophthalmol Vis Sci. 2011;52:772–77. In this paper it is shown that multifocal electroretinogram (mfERG) implicit time (IT) is a good predictor of DR onset. It can be used not only to assess the risk of DR development but also as a valuable outcome measure in the evaluation of novel treatments based on neuroprotection. PubMedCrossRef

28.

Ng YK, Zeng XX, Ling EA. Expression of glutamate receptors and calcium-binding proteins in the retina of streptozotocin-induced diabetic rats. Brain Res. 2004;1018:66–72.PubMedCrossRef

29.

Pulido JE, Pulido JS, Erie JC, et al. A role for excitatory amino acids in diabetic eye disease. Exp Diabetes Res. 2007;2007:36150.PubMedCrossRef

30.

• Silva KC, Rosales MA, Biswas SK et al. Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. Diabetes. 2009;58:1382–90. This paper provided first evidence of angiotensin II type I receptor blockade as a neuroprotective treatment of diabetic retinopathy by reestablishing oxidative redox and mitochondrial function.PubMedCrossRef

31.

•• Zong H, Ward M, Madden A et al. Hyperglycemia-induced proinflammatory reponses by retinal Müller glia are regulated by receptor for advanced glycation end-products (RAGE) Diabetologia 2010;53:2656–66. In this paper the authors demonstrated that hyperglycaemia in vivo and in vitro exposure to high glucose induce upregulation of RAGE and its ligands, leading to RAGE signalling, which links to pro-inflammatory responses by retinal Müller glia. These data shed light on the potential clinical application of RAGE blockade to inhibit the progression of diabetic retinopathy. PubMedCrossRef

32.

• Berner AK, Brouwers O, Pringle R et al. Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia. 2012;55:845–54. In this paper the authors provide evidence that detoxification of methylglyoxal (an important precursor of AGEs) reduces AGE adduct accumulation, which, in turn, can prevent the formation of key retinal neuroglial and vascular lesions as diabetes progresses. PubMedCrossRef

33.

Wilkinson-Berka JL. Angiotensin and diabetic retinopathy. Int J Biochem Cell Biol. 2006;38:752–65.PubMedCrossRef

34.

Kurihara T, Ozawa Y, Nagai N, et al. Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes. 2008;57:2191–8.PubMedCrossRef

35.

Downie LE, Pianta MJ, Vingrys AJ, et al. AT1 receptor inhibition prevents astrocyte degeneration and restores vascular growth in oxigen-induced retinopathy. Glia. 2008;56:1076–90.PubMedCrossRef

36.

Villarroel M, Ciudin A, Hernández C, Simó R. Neurodegeneration: an early event of diabetic retinopathy. World J Diabetes. 2010;1:57–64.PubMedCrossRef

37.

Shoham S, Bejar C, Kovalev E, et al. Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats. Neuropharmacology. 2007;52:836–43.PubMedCrossRef

38.

Cheung AK, Fung MK, Lo AC, et al. Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes. 2005;54:3119–25.PubMedCrossRef

39.

Kusari J, Zhou S, Padillo E, et al. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci. 2007;48:5152–9.PubMedCrossRef

40.

Metea MR, Newman EA. Signalling within the neurovascular unit in the mammalian retina. Exp Physiol. 2007;92:635–40.PubMedCrossRef

41.

• Feng Y, Wang Y, Stock O et al. Vasoregression linked to neuronal damage in the rat with defect of polycystin-2. PLoS One. 2009;4(10):e7328. In this paper the authors show by using a transgenic rat with overexpression of a mutant cilia gene polycystin-2 the temporal link between neuronal damage and vasoregression. PubMedCrossRef

42.

Feng Y, Wang Y, Li L, et al. Gene expression profiling of vasoregression in the retina--involvement of microglial cells. PLoS One. 2011;17(6):e16865.CrossRef

43.

Cervantes-Villagrana AR, García-Román J, González-Espinosa C, Lamas M. Pharmacological inhibition of N-methyl d-aspartate receptor promotes secretion of vascular endothelial growth factor in müller cells: effects of hyperglycemia and hypoxia. Curr Eye Res. 2010;35:733–41.PubMedCrossRef

44.

• Kusari J, Zhou SX, Padillo E et al. Inhibition of vitreoretinal VEGF elevation and blood-retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine. Invest Ophthalmol Vis Sci. 2010;51:1044–51. In this paper it is demonstrated that brimonidine (an alpha-2 agonist) downregulates VEGF and inhibits the blood-retinal barrier breakdown. This study suggests the role of neurotransmitters in the pathogenesis of DR.PubMedCrossRef

45.

Formaz F, Riva CE, Geiser M. Diffuse luminance flicker increases retinal vessel diameter in humans. Curr Eye Res. 1997;16:1252–7.PubMedCrossRef

46.

Riva CE, Logean E, Falsini B. Visually evoked hemodynamical response and assessment of neurovascular coupling in the optic nerve and retina. Prog Retin Eye Res. 2005;24:183–215.PubMedCrossRef

47.

Nguyen TT, Kawasaki R, Wang JJ, Kreis AJ, Shaw J, Vilser W, Wong TY. Flicker light-induced retinal vasodilation in diabetes and diabetic retinopathy. Diabetes Care. 2009;32:2075–80.PubMedCrossRef

48.

•• Lecleire-Collet A, Audo I, Aout M et al. Evaluation of retinal function and flicker light-induced retinal vascular response in normotensive patients with diabetes without retinopathy. Invest Ophthalmol Vis Sci. 20;52:2861–7. In this study it is shown that vascular response to flicker light is impaired in patients with diabetes without DR in comparison with controls. These results suggest that, both neural and neurovascular dysfunctions precede the onset of clinically detectable DR.

49.

Loomans CJ, van Haperen R, Duijs JM, et al. Differentiation of bone marrow-derived endothelial progenitor cells is shifted into a proinflammatory phenotype by hyperglycemia. Mol Med. 2009;15:152–9.PubMedCrossRef

50.

Barnstable CJ, Tombran-Tink J. Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential. Prog Retin Eye Res. 2004;23:561–77.PubMedCrossRef

51.

Shen X, Xie B, Cheng Y, et al. Effect of pigment epithelium derived factor on the expression of glutamine synthetase in early phase of experimental diabetic retinopathy. Ocul Immunol Inflamm. 2011;19:246–54.PubMedCrossRef

52.

Cervia D, Casini G, Bagnoli P. Physiology and pathology of somatostatin in the mammalian retina: a current view. Mol Cell Endocrinol. 2008;286:112–22.PubMedCrossRef

53.

Simó R, Lecube A, Sararols L, et al. Deficit of somatostatin-like immunoreactivity in the vitreous fluid of diabetic patients: possible role in the development of proliferative diabetic retinopathy. Diabetes Care. 2002;25:2282–6.PubMedCrossRef

54.

Hernández C, Carrasco E, Casamitjana R, et al. Somatostatin molecular variants in the vitreous fluid: a comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects. Diabetes Care. 2005;28:1941–7.PubMedCrossRef

55.

Simó R, Carrasco E, García-Ramírez M, Hernández C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev. 2006;2:71–98.PubMedCrossRef

56.

Lambooij AC, Kuijpers RW, van Lichtenauer-Kaligis EG, et al. Somatostatin receptor 2A expression in choroidal neovascularization secondary to age related macular degeneration. Invest Ophthalmol Vis Sci. 2000;41:2329–35.PubMed

57.

Kiagiadaki F, Savvaki M, Thermos K. Activation of somatostatin receptor (sst 5) protects the rat retina from AMPA-induced neurotoxicity. Neuropharmacology. 2010;58:297–303.PubMedCrossRef

58.

Simó R, Carrasco E, Fonollosa A, et al. Deficit of somatostatin in the vitreous fluid of patients with diabetic macular edema. Diabetes Care. 2007;30:725–7.PubMedCrossRef

59.

Hernández C, Simó R. Strategies for blocking angiogenesis in diabetic retinopathy: fom basic science to clinical practice. Expert Opin Invest Drugs. 2007;16:1209–26.CrossRef

60.

Grant MB, Mames RN, Fitzgeral C, et al. The efficacy of octreotide in the therapy of severe non-proliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care. 2000;23:504–9.PubMedCrossRef

61.

Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE. Octreotide reduces vitreous hemorrhage and loss of visual acuity in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res. 2001;33:300–6.PubMedCrossRef

62.

Jansen J, Lamberts S. Circulating IGF-1 and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol. 2000;52:1–9.CrossRef

63.

Wang Q, Dills D, Klein R, Klein B, Moss S. Does insulin-like growth factor predict incidende and progression of diabetic retinopathy? Diabetes. 1995;44:161–4.PubMedCrossRef

64.

Growth hormone Antagonist for Proliferative Diabetic Retinopathy. The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 2001;108:2266–2272.

65.

Marti HH. Erythropoietin and the hypoxic brain. J Exp Biol. 2004;207:3233–42.PubMedCrossRef

66.

Hernández C, Fonollosa A, García-Ramírez M, et al. Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care. 2006;29:2028–33.PubMedCrossRef

67.

Becerra SP, Amaral J. Erythropoietin: an endogenous retinal survival factor. N Engl J Med. 2002;347:1968–70.PubMedCrossRef

68.

Rex TS, Wong Y, Kodali K, Merry S. Neuroprotection of photoreceptors by direct delivery of erythropoietin to the retina of the retinal degeneration slow mouse. Exp Eye Res. 2009;89:735–40.PubMedCrossRef

69.

Shen J, Wu Y, Xu JY, et al. ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD. Invest Ophthalmol Vis Sci. 2010;5:35–46.CrossRef

70.

• García-Ramírez M, Hernández C, Simó R. Expression of erythropoietin and its receptor in the human retina: a comparative study of diabetic and nondiabetic subjects. Diabetes Care 2008;31:1189–1194. This paper demonstrated that Epo overexpression is an early event in the retina of diabetic patients and that this is not associated with any change in EpoR. At this early stage, other factors apart from hypoxia seem to be more important in accounting for the Epo upregulation that exists in the diabetic retina. PubMedCrossRef

71.

Katsura Y, Okano T, Matsuno K, et al. Erythropoietin is highly elevated in vitreous fluid of patients with proliferative diabetic retinopathy. Diabetes Care. 2005;28:2252–4.PubMedCrossRef

72.

Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353:782–92.PubMedCrossRef

73.

Jaquet K, Krause K, Tawakol-Khodai M, et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res. 2002;64:326–33.PubMedCrossRef

74.

García-Arumí J, Fonollosa A, Macià C, et al. Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: a comparative study with diabetic macular oedema. Eye. 2009;23:1066–71.PubMedCrossRef

75.

Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest. 2008;118:526–33.PubMed

76.

Zhang J, Wu Y, Jin Y, et al. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci. 2008;49:732–42.PubMedCrossRef

77.

• Wang Q, Gorbey S, Pfister F et al. Long-term treatment with suberythropoietic Epo is vaso- and neuroprotective in experimental diabetic retinopathy. Cell Physiol Biochem 2011;27:769–782. In this manuscript the authors show in streptozotocin-diabetic Wistar rats that neurodegeneration in the diabetic retina was significantly reduced by Epo treatment. In addition, increased VEGF-A levels in the diabetic retina were normalized by Epo treatment. PubMedCrossRef

78.

Garcia-Ramírez M, Hernández C, Ruiz-Meana M, et al. Erythropoietin protects retinal pigment epithelial cells against the increase of permeability induced by diabetic conditions: essential role of JAK2/ PI3K signaling. Cell Signal. 2011;23:1596–602.PubMedCrossRef

79.

Grant MB, Boulton ME, Ljubimov AV. Erythropoietin: when liability becomes asset in neurovascular repair. J Clin Invest. 2008;118:467–70.PubMedCrossRef

80.

Lagrèze WA, Feltgen N, Bach M, Jehle T. Feasibility of intravitreal erythropoietin injections in humans. Br J Ophthalmol. 2009;93:1667–71.PubMedCrossRef

81.

Li W, Sinclair SH, Xu GT. Effects of ontravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema. Ophthalmic Surg Lasers Imaging. 2010;41:18–25.PubMedCrossRef

82.

Stahl A, Krohne TU, Sapieha P, et al. Lipid metabolites in the pathogenesis and treatment of neovascular eye disease. Br J Ophthalmol. 2011;95:1496–501.PubMedCrossRef

83.

SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res. 2005;24:87–138.PubMedCrossRef

84.

Bazan NG. Neurotrophins induce neuroprotective signaling in the retinal pigment epithelial cell by activating the synthesis of the anti-inflammatory and anti-apoptotic neuroprotectin D1. Adv Exp Med Biol. 2008;613:39–44.PubMedCrossRef

85.

Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A. 2004;101:8491–6.PubMedCrossRef

86.

Bordet R, Ouk T, Petrault O, et al. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans. 2006;34:1341–6.PubMedCrossRef

87.

Deplanque D, Gelé P, Pétrault O, et al. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci. 2003;23:6264–71.PubMed

88.

Bhateja DK, Dhull DK, Gill A, et al. Peroxisome proliferator-activated receptor-α activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms. Eur J Pharmacol. 2012;674:33–43.PubMedCrossRef

89.

Dong CJ, Guo Y, Agey P, et al. Alpha 2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci. 2008;49:4515–22.PubMedCrossRef

90.

Saylor M, McLoon LK, Harrison AR, Lee MS. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol. 2009;127:402–6.PubMedCrossRef

91.

Eljarrat-Binstock E, Pe'er J, Domb AJ. New techniques for drug delivery to the posterior eye segment. Pharm Res. 2010;27:530–43.PubMedCrossRef

92.

Lambiase A, Aloe L, Centofanti M, et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma. Proc Natl Acad Sci USA. 2008;106:13469–74.CrossRef

93.

Aiello LP. Targeting intraocular neovascularization and edema-one drop at a time. N Engl J Med. 2008;359:967–9.PubMedCrossRef

Titel: Neuroprotection in Diabetic Retinopathy
verfasst von: Cristina Hernández
Rafael Simó
Publikationsdatum: 01.08.2012
Verlag: Current Science Inc.
Erschienen in: Current Diabetes Reports / Ausgabe 4/2012
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-012-0284-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Screening for Diabetic Retinopathy and Diabetic Macular Edema in the United Kingdom

Novel Targets Against Retinal Angiogenesis in Diabetic Retinopathy

Neuropathic Pain: Is Quantitative Sensory Testing Helpful?

Management of Painful Diabetic Neuropathy: Guideline Guidance or Jungle?

Cancer Risk in Type 2 Diabetes